EPRX — EUPRAXIA PHARMACEUTICALS INC.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2024-04-05.
Performance
Technicals
Others in Healthcare
Measured signals that fired on EPRX
| date | signal | measured base rate |
|---|---|---|
| 2026-05-15 | Institutional holders jumped in a quarter ownership | -0.52% over 21 days · t = -0.38 · n = 1,553 not distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Affinity Asset Advisors, LLC | 11.5M | 1.6M |
| Balyasny Asset Management L.P. | 9.8M | 1.4M |
| Vivo Capital, LLC | 9.8M | 1.4M |
| Ikarian Capital, LLC | 8.8M | 1.2M |
| GREAT POINT PARTNERS LLC | 8.7M | 1.2M |
| SCOTIA CAPITAL INC. | 7.2M | 1.3M |
| Point72 Asset Management, L.P. | 7.0M | 967.6K |
| UBS Group AG | 5.5M | 762.6K |
| Redmile Group, LLC | 5.1M | 700.0K |
| Rubric Capital Management LP | 5.0M | 691.2K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about EPRX
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →